Cancer Immunotherapy: The 2018 Dr. Paul Janssen Award Symposium | The New York Academy of Sciences
×

WE HAVE UPDATED OUR PRIVACY POLICY. For further information, see https://www.nyas.org/about/privacy-policy.

Cancer Immunotherapy: The 2018 Dr. Paul Janssen Award Symposium

FREE

for Members

Cancer Immunotherapy: The 2018 Dr. Paul Janssen Award Symposium

Wednesday, September 12, 2018, 8:00 AM - 2:30 PM

The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St Fl 40, New York

Presented By

 

Cancer immunotherapies utilize the body’s own immune defenses to kill tumor cells. James P. Allison, PhD, of the University of Texas MD Anderson Cancer Center has dedicated his career to better understanding the immune system and leveraging it to treat cancer. Dr. Allison led the development of ipilimumab, a cancer immunotherapy that targets CTLA-4, a receptor that effectively turns “off” immune cells. By inhibiting CTLA-4, ipilimumab activates the immune response to target and kill cancer cells. Ipilimumab was the first immune checkpoint inhibitor approved by the U.S. Food and Drug Administration, achieving long-standing remission of metastatic melanoma in some cases. Its success has helped to establish immunotherapy as a viable and effective strategy more broadly. For his extensive characterization of immune regulation and development of therapies that have dramatically improved the treatment of certain cancers, Dr. Allison will receive the 2018 Dr. Paul Janssen Award for Biomedical Research.

Similar to ipilimumab, other immune checkpoint inhibitors that activate the immune response to cancer through different molecular targets also have recently been deployed to treat a number of different cancers. Beyond immune checkpoint blockade, the field of immune-oncology has grown to include several therapeutic strategies, currently in various stages of development — including cytokine therapy, cancer vaccines, and harvesting and modifying patients’ immune cells (as in CAR-T treatments). Further studies of the immune response to cancer, and of the dynamics of the broader tumor microenvironment, will aid the development and optimization of these therapies. Work is ongoing to apply immunotherapies to new cancers and patients, to understand how best to use them in combination, and to reduce the risk of potentially dangerous side effects.

This half-day symposium, Cancer Immunotherapy: The 2018 Dr. Paul Janssen Award Symposium, will celebrate the work of Dr. Allison, who will review recent advances. Following his award lecture, fellow prominent scientists will discuss several aspects of cancer immunotherapy, from the basic understanding of immune regulation to the development of therapies in the clinic.

Registration

Speakers

Cancer Immunotherapy: The 2018 Dr. Paul Janssen Award Symposium
Elizabeth Mittendorf, MD, PhD, Brigham and Women’s Hospital; Dana-Farber Cancer Institute
Cancer Immunotherapy: The 2018 Dr. Paul Janssen Award Symposium
Matthew Mulvey, PhD, BeneVir
Cancer Immunotherapy: The 2018 Dr. Paul Janssen Award Symposium
Dana Pe'er, PhD, Memorial Sloan Kettering Cancer Center
This symposium is made possible with support from:


Wednesday

September 12, 2018

8:00 AM

Registration and Breakfast

9:00 AM

Welcome and Introductory Remarks

SESSION I: The Past and the Future of Cancer Immunotherapy

9:10 AM

2018 Dr. Paul Janssen Award for Biomedical Research Announcement

9:20 AM

2018 Dr. Paul Janssen Award for Biomedical Research Lecture

Speaker

James P. Allison, PhD
The University of Texas MD Anderson Cancer Center

SESSION II: Emerging Approaches in Cancer Immunotherapy

10:10 AM

TBD

Speaker

Dana Pe'er, PhD
Memorial Sloan Kettering Cancer Center
10:35 AM

TBD

Speaker

Alexander Rudensky, PhD
Memorial Sloan Kettering Cancer Center
11:00 AM

Coffee and Networking Break

11:30 AM

TBD

Speaker

Elizabeth Mittendorf, MD, PhD
Brigham and Women’s Hospital; Dana-Farber Cancer Institute
11:55 AM

TBD

Speaker

Padmanee Sharma, MD, PhD
The University of Texas MD Anderson Cancer Center
12:20 PM

Oncolytic Viruses: Past Present Future

Speaker

Matthew Mulvey, PhD
BeneVir
12:45 PM

Panel Discussion

1:15 PM

Luncheon

2:30 PM

Adjourn

This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.